Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b

doi:10.3748/wjg.v23.i46.8120

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 46

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9580)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

476

WORD

268

HTML

4850

Figures (1-1)

299

Tables (1-3)

310

Sum=6203

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

635

Download

670

Sum=1305

Publishing Process of This Article

Item

Count

Browse

981

Download

1091

Sum=2072

Dec 14, 2017 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Dec 14, 2017; 23(46): 8120-8127
Published online Dec 14, 2017. doi: 10.3748/wjg.v23.i46.8120

Table 1 Representative direct-acting antivirals, their targets and hepatitis C virus genotypes

Target regions	DAAs	HCV GTs
NS3/4A	Glecaprevir	Pan-GTs
	Grazoprevir	1, 4
	Asunaprevir	1b
	Paritaprevir	1, 2a, 4
	Simeprevir	1, 4
	Telaprevir	1, 2
	Boceprevir	1
NS5A	Pibrentasvir	Pan-GTs
	Velpatasvir	Pan-GTs
	Elbasvir	Pan-GTs
	Daclatasvir	Pan-GTs
	Ledipasvir	1, 4, 5
	Ombitasvir	1, 4
NS5B	Sofosbuvir [nucleos(t)ide inhibitor]	Pan-GTs
	Dasabuvir [non-nucleos(t)ide inhibitor]	1

DAAs: Direct-acting antivirals; HCV GTs: Hepatitis C virus genotypes.

Citation: Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World J Gastroenterol 2017; 23(46): 8120-8127
URL: https://www.wjgnet.com/1007-9327/full/v23/i46/8120.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i46.8120